Altermed Co.,Ltd. Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2019
NCT04372355
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Altermed Co.,Ltd.

Active Ingredients

Drugs in Phase 2 Trials (1)

Tetrachlorodecaoxide (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetic Foot (Phase 2)

Foot Ulcer (Phase 2)

Ulcer (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1